Kathleen Ford Sells 6,892 Shares of Kura Oncology (NASDAQ:KURA) Stock

Key Points

• Kura Oncology's COO, Kathleen Ford, sold 6,892 shares of the stock at an average price of $8.94, resulting in a total transaction of approximately $61,614.48, marking a 9.81% decrease in her ownership.
• The company's stock price fell by 0.9% to $8.97 with a market cap of $778.60 million and a 12-month low of $5.41.
• Kura Oncology reported a loss of ($0.75) earnings per share for the last quarter, missing analysts' estimates, and had revenues of $15.29 million compared to expectations of $64.95 million.

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) COO Kathleen Ford sold 6,892 shares of the stock in a transaction on Monday, September 29th. The stock was sold at an average price of $8.94, for a total transaction of $61,614.48. Following the transaction, the chief operating officer directly owned 63,375 shares in the company, valued at approximately $566,572.50. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kura Oncology Stock Down 0.9%

NASDAQ KURA traded down $0.08 on Monday, hitting $8.97. 2,168,205 shares of the company were exchanged, compared to its average volume of 1,613,537. The company has a market cap of $778.60 million, a PE ratio of -3.97 and a beta of 0.19. Kura Oncology, Inc. has a 12 month low of $5.41 and a 12 month high of $19.93. The stock has a fifty day moving average of $7.39 and a 200-day moving average of $6.65. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.90). The company had revenue of $15.29 million for the quarter, compared to analyst estimates of $64.95 million. As a group, analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Institutional Trading of Kura Oncology

Institutional investors and hedge funds have recently made changes to their positions in the company. BVF Inc. IL increased its holdings in Kura Oncology by 202.0% during the first quarter. BVF Inc. IL now owns 7,754,129 shares of the company's stock worth $51,177,000 after buying an additional 5,186,660 shares during the last quarter. Armistice Capital LLC increased its holdings in Kura Oncology by 13.3% during the first quarter. Armistice Capital LLC now owns 6,572,000 shares of the company's stock worth $43,375,000 after buying an additional 772,000 shares during the last quarter. Vanguard Group Inc. increased its holdings in Kura Oncology by 2.7% during the first quarter. Vanguard Group Inc. now owns 4,948,235 shares of the company's stock worth $32,658,000 after buying an additional 129,337 shares during the last quarter. EcoR1 Capital LLC increased its holdings in Kura Oncology by 59.1% during the second quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company's stock worth $24,234,000 after buying an additional 1,559,702 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Kura Oncology by 11.7% during the second quarter. Geode Capital Management LLC now owns 2,014,029 shares of the company's stock worth $11,623,000 after buying an additional 211,470 shares during the last quarter.

Analyst Ratings Changes

A number of research firms have weighed in on KURA. Wedbush reaffirmed an "outperform" rating and issued a $36.00 price objective on shares of Kura Oncology in a research note on Friday, June 20th. Guggenheim began coverage on shares of Kura Oncology in a research note on Thursday, September 4th. They issued a "neutral" rating on the stock. JMP Securities dropped their price objective on shares of Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating on the stock in a research note on Monday, August 11th. Wall Street Zen upgraded shares of Kura Oncology from a "sell" rating to a "hold" rating in a report on Sunday, August 17th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Kura Oncology in a report on Thursday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Kura Oncology currently has a consensus rating of "Moderate Buy" and a consensus target price of $24.10.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.